SUNNYVALE, Calif., Nov. 1, 2022
/PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today
that the registration dossier for the CNNC-Accuray joint venture
Tomo® C radiation therapy system for the Type B market
has been submitted to the Chinese National Medical Products
Administration (NMPA). This milestone aligns with the timeline
communicated by Accuray during the company's Q4 FY2022 earnings
call. The availability of Tomo C is subject to review and approval
by the NMPA. The new made in China
system, designed specifically to expand access to precise radiation
treatments to more cancer patients in China, is the first joint venture product.
The number of new cancer cases diagnosed in China is anticipated to increase by
approximately 50 percent from 2020 to 20401, with
increases in the incidence of not just lung cancer, but also
colorectum, breast and prostate cancers2. Radiation
therapy is one of the primary treatment options for lung, breast
and prostate cancers, reinforcing the need for innovative new
approaches that effectively manage the disease while minimizing the
risk of side effects and their impact on quality of life.
"The submission of the Tomo C dossier is an important step for
the CNNC-Accuray joint venture and represents an important growth
catalyst for Accuray. I'm confident that the system will
significantly enhance the joint venture's product portfolio and
ability to compete in the large and rapidly growing Type B segment
in the future. The team's focus on ensuring we have the right
products to address the needs of the Chinese radiation therapy
market – the fastest growing in the world – will enable more people
in China to get the care that is
essential to their long-term health," said Suzanne Winter, president and chief executive
officer of Accuray.
The TomoTherapy® platform is the first in the world
capable of integrated helical fan beam imaging and radiation
delivery, providing greater control of the radiation dose so it
conforms precisely to the tumor and provides superior normal tissue
preservation, enabling delivery of conventionally fractionated to
ultra-hypofractionated treatments. The system is capable of
treating all standard radiation therapy indications including
breast, prostate, lung, abdominal, and head and neck cancers, in
addition to complex treatments such as total marrow
irradiation.
"This submission and the manufacture of a locally made
TomoTherapy platform device underscores Accuray's commitment to the
joint venture. I believe Tomo C will meet the requirements of the
majority of Chinese customers who need a radiation delivery system
that is effective and fast. This first China-made system will enable Chinese
customers to offer highly precise radiation therapy to more
patients each day," said Dr. Roger
Cao, president & general manager APAC at Accuray.
About Accuray
Accuray is committed to expanding the powerful potential of
radiation therapy to improve as many lives as possible. We invent
unique, market-changing solutions that are designed to deliver
radiation treatments for even the most complex cases—while making
commonly treatable cases even easier—to meet the full spectrum of
patient needs. We are dedicated to continuous innovation in
radiation therapy for oncology, neuro-radiosurgery, and beyond, as
we partner with clinicians and administrators, empowering them to
help patients get back to their lives, faster. Accuray is
headquartered in Sunnyvale,
California, with facilities worldwide. To learn more, visit
https://www.accuray.com/ or follow us on Facebook, LinkedIn,
Twitter, and YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to anticipated growth
catalysts for the company, the enhancement of the joint venture's
product portfolio, the joint venture's ability to compete in the
growing Type B segment, the ability of the Tomo C system to meet
Chinese customer needs, clinical applications, clinical results,
patient outcomes and Accuray's leadership position in radiation
oncology innovation and technologies. These forward-looking
statements involve risks and uncertainties. If any of these risks
or uncertainties materialize, or if any of the company's
assumptions prove incorrect, actual results could differ materially
from the results expressed or implied by these forward-looking
statements. These risks and uncertainties include, but are not
limited to, risks related to the global macroeconomic environment;
the effect of Covid-19; the company's ability to achieve widespread
market acceptance of its products, including new product offerings
and improvements; the company's ability to develop new products or
improve existing products to meet customers' needs; and such other
risks identified under the heading "Risk Factors" in the company's
Annual Report on Form 10-K, filed with the Securities and Exchange
Commission (the "SEC") on August 17,
2022, and as updated periodically with the company's other
filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Media Contact:
Beth
Kaplan
Public Relations Director,
Accuray
+1 (408)
789-4426
bkaplan@accuray.com
1
https://gco.iarc.fr/tomorrow/en/dataviz/bars?mode=population&populations=935_160
2 Xia C, Dong X, Li H, Cao M, Sun D, He S, Yang F, Yan
X, Zhang S, Li N, Chen W. Cancer
statistics in China and
United States, 2022: profiles,
trends, and determinants. Chin Med J (Engl). 2022 Feb 9;135(5):584-590. doi:
10.1097/CM9.0000000000002108. PMID: 35143424; PMCID: PMC8920425
View original content to download
multimedia:https://www.prnewswire.com/news-releases/accuray-announces-tomo-c-registration-submission-to-chinas-national-medical-products-administration-301664095.html
SOURCE Accuray Incorporated